Business
Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting
WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,
About this update from Disc Medicine, Inc.
[{"type":"text","content":"WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of myelofibrosis (MF) in an oral abstract session at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held in Chicago, IL on May 29-June 2, 2026. “Initial data from the RALLY-MF trial showed anemia response rates that are unprecedented in the hard-to-treat myelofibrosis population,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc Medicine. “We look forward to bringing a more complete dataset, with additional data from patients receiving transfusions, to the ASCO stage.” The abstract will be published online on the ASCO conference website on May 21, 2026. Pursuant to Disc Medicine practice, the abstract published will contain previously presented data, and new data and analyses are reserved for presentation at the conference. DISC-0974 is an investigational agent and is not approved for use as a therapy in any jurisdiction worldwide. Details of Oral Presentation: Abstract Number: 6501 Abstract Title: RALLY-MF: Initial efficacy of a phase 2 study of DISC-0974, an anti-hemojuvelin antibody, to treat anemia in myelofibrosis. Session Type/Title: Oral Abstract Session - Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Session Date and Time: June 2, 2026, 9:45 AM-12:45 PM CDTPresenting Author: Naseema Gangat, M.B.B.S. About Disc Medicine Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com. Disc Cautionary Statement Regarding Forward-Looking Statements This press release contains “forward-looking s...